SEC Form 4 · accession 0000899243-19-006336

GW PHARMACEUTICALS PLC · GWPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Mar 1, 2019

Accepted (ET)

Mar 5, 2019 · 9:07 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001351288

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Options^F1,F2,F3	$14.33	Mar 1, 2019	A	119,472	A	Mar 1, 2022	Mar 1, 2029	Ordinary Shares	119,472	119,472	D
Stock Options^F1,F4	$0.0013	Mar 1, 2019	A	226,752	A	Mar 1, 2022	Mar 15, 2023	Ordinary Shares	226,752	226,752	D
Stock Options^F1,F4,F5	$0.0013	Mar 1, 2019	A	17,004	A	Mar 1, 2020	—	Ordinary Shares	17,004	17,004	D
Stock Options^F1,F4,F5	$0.0013	Mar 1, 2019	A	17,004	A	Mar 1, 2021	—	Ordinary Shares	17,004	17,004	D
Stock Options^F1,F4,F5	$0.0013	Mar 1, 2019	A	17,004	A	Mar 1, 2022	—	Ordinary Shares	17,004	17,004	D
Stock Options^F1,F4,F5	$0.0013	Mar 1, 2019	A	17,004	A	Mar 1, 2023	—	Ordinary Shares	17,004	17,004	D

F1Granted pursuant to the Issuer's Long-Term Incentive Plan.
F2The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer.
F3The exercise price reported is price per ordinary share converted from price per ADS ($172.01).
F4Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019.
F5These stock options will vest automatically on exercisable date.